
Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
139.3075
Open
137.380
VWAP
134.58
Vol
473.83K
Mkt Cap
8.82B
Low
131.280
Amount
63.77M
EV/EBITDA(TTM)
13.74
Total Shares
66.26M
EV
10.60B
EV/OCF(TTM)
16.48
P/S(TTM)
2.80
AptarGroup, Inc. is engaged in designing and manufacturing of drug and consumer product dosing, dispensing and protection technologies. The Company serves various end markets, including pharmaceutical, beauty, food, beverage, personal care and home c...Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q1
FY2025Q2
FY2025Q3
894.26M
-2.31%
1.155
-8.33%
919.43M
+1.03%
1.407
+2.68%
927.26M
+1.98%
1.565
+5.03%
Estimates Revision
The market is revising Downward the revenue expectations for AptarGroup, Inc. (ATR) for FY2025, with the revenue forecasts being adjusted by -2.58% over the past three months. During the same period, the stock price has changed by -13.29%.
Revenue Estimates for FY2025
Revise Downward

-2.58%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward

-4.73%
In Past 3 Month
Stock Price
Go Down

-13.29%
In Past 3 Month
6 Analyst Rating

35.04% Upside
Wall Street analysts forecast ATR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ATR is 180.50 USD with a low forecast of 160.00 USD and a high forecast of 205.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
1 Hold
0 Sell
Strong Buy

35.04% Upside
Current: 133.660

Low
160.00
Averages
180.50
High
205.00
Baird
Ghansham Panjabi
Buy
Maintains
$185 → $160
2025-02-10
Reason
Baird analyst Ghansham Panjabi lowered the firm's price target on AptarGroup to $160 from $185 and keeps an Outperform rating on the shares. The firm said they see near-term headwinds but the long sterm story remains intact.
Wells Fargo
Gabe Hajde
Buy
Maintains
$180 → $170
2025-02-10
Reason
Wells Fargo lowered the firm's price target on AptarGroup to $170 from $180 and keeps an Overweight rating on the shares. The firm notes AptarGroup's shares "took a beating" on Friday, owing to comments on tax, FX being a 2025 EPS headwind and a quarterly slowdown in Pharma organic growth. However, underlying performance "remains superb" with Well's long-term thesis unchanged, the firm adds.
Raymond James
Matt Roberts
Buy
Reiterates
$200 → $190
2025-02-10
Reason
Raymond James
Matt Roberts
Buy
Initiates
$200
2025-01-07
Reason
Raymond James initiated coverage of AptarGroup with an Outperform rating and $200 price target.
Wells Fargo
Gabe Hajde
Buy
Maintains
$185 → $180
2025-01-06
Reason
Baird
Ghansham Panjabi
Buy
Maintains
$170 → $185
2024-10-28
Reason
Baird raised the firm's price target on AptarGroup to $185 from $170 and keeps an Outperform rating on the shares. The firm said AptarGroup is well-positioned to deliver a high-quality DD earnings growth algorithm, propagated by growth in Pharmaceuticals, cost-out initiatives in Packaging that should increase operating leverage as volumes eventually normalize, and capital allocation optionality inclusive of share buybacks.
Wells Fargo
Gabe Hajde
Buy
Maintains
$168 → $185
2024-10-15
Reason
Wells Fargo raised the firm's price target on AptarGroup to $185 from $168 and keeps an Overweight rating on the shares. Discussing the packaging and containers industry ahead of quarterly results, the firm says that while it believes Q3 demand improved sequentially, Wells doesn't expect anything heroic given caution from both consumers and industrial sectors. The firm thinks the worst is now behind, but says its base case remains more muted, as it assumes volumes trend flat, rather than +low single-digits for the full year, and recovery likely pushed out to the first half of 2025. Wells keeps AptarGroup (ATR), Ardagh Metal Packaging (AMBP), and Crown Holdings (CCK) as its top picks into Q3.
Jefferies
Daniel Rizzo
Hold
to
Strong Buy
Upgrades
$155 → $215
2024-10-14
Reason
Jefferies upgraded AptarGroup to Buy from Hold with a price target of $215, up from $155. With a strong pipeline of new products such as delivery systems for GLP-1 drugs, for over-the-counter Narcan, and for Neffy, AptarGroup's Pharma segment will lead an 8.5% annual EBITDA growth through 2026, the analyst tells investors in a research note. The firm expects the stock's valuation to continue to move towards that of its healthcare packaging competitors.
Wells Fargo
Gabe Hajde
Buy
Maintains
$163 → $168
2024-07-17
Reason
Baird
Ghansham Panjabi
Buy
Maintains
$150 → $170
2024-04-29
Reason
Valuation Metrics
The current forward P/E ratio for Aptargroup Inc (ATR.N) is 24.24, compared to its 5-year average forward P/E of 28.70. For a more detailed relative valuation and DCF analysis to assess Aptargroup Inc 's fair value, click here.
Forward PE

Undervalued
5Y Average PE
28.70
Current PE
24.24
Overvalued PE
32.36
Undervalued PE
25.05
Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
13.69
Current EV/EBITDA
12.60
Overvalued EV/EBITDA
14.90
Undervalued EV/EBITDA
12.48
Forward PS

Fair
5Y Average PS
2.47
Current PS
2.54
Overvalued PS
2.77
Undervalued PS
2.16
Financials
Annual
Quarterly
FY2024Q4
YoY :
+1.15%
848.09M
Total Revenue
FY2024Q4
YoY :
+12.43%
123.45M
Operating Profit
FY2024Q4
YoY :
+62.05%
100.87M
Net Income after Tax
FY2024Q4
YoY :
+59.14%
1.48
EPS - Diluted
FY2024Q4
YoY :
-20.45%
107.71M
Free Cash Flow
FY2024Q4
YoY :
+4.50%
30.89
Gross Profit Margin - %
FY2024Q4
YoY :
+32.47%
9.75
FCF Margin - %
FY2024Q4
YoY :
+60.24%
11.89
Net Margin - %
FY2024Q4
YoY :
+25.00%
11.75
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
528.3K
USD
3
6-9
Months
16.2M
USD
11
0-12
Months
1.3M
USD
3
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
435.1K
Volume
4
6-9
Months
0.0
Volume
0
0-12
Months
1.1M
Volume
2
Bought
0-3
0
0.0
Volume
Months
3-6
1
1.6K
Volume
Months
6-9
0
0.0
Volume
Months
0-12
6
14.8K
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
ATR News & Events
Events Timeline
2025-02-06 (ET)
2025-02-06
16:19:28
AptarGroup reports Q4 adjusted EPS $1.52, consensus $1.26

2024-10-24 (ET)
2024-10-24
17:03:15
AptarGroup reports Q3 EPS $1.49, consensus $1.42

2024-10-22 (ET)
2024-10-22
17:06:49
AptarGroup awarded $4.8M U.S. federal contract for ActivShield technology

2024-10-10 (ET)
2024-10-10
17:02:20
AptarGroup authorizes share repurchase of up to $500M, declares 45c dividend

2024-09-23 (ET)
2024-09-23
17:02:36
AptarGroup's N-Sorb nitrosamine mitigation solution accepted to FDA ETP

News
2.0
03-27NewsfilterAptar Named One of Barron's 100 Most Sustainable U.S. Companies for the Seventh Consecutive Year
8.0
03-20NewsfilterAptar Recognized with Prestigious 'A' Score on the CDP Climate Change Assessment
6.5
03-20SeekingAlphaBofA picks 36 stocks to help weather market downturns
1.0
02-27BusinesswireSamenvatting: RDD Europe 2025, georganiseerd door Aptar Pharma en RDD Online, viert 20-jarig bestaan
1.0
02-27BusinesswireResumen: RDD Europe 2025, coorganizado por Aptar Pharma y RDD Online, celebra 20 años
1.0
02-27BusinesswireRiassunto: RDD Europe 2025, organizzata da Aptar Pharma e RDD Online, festeggia il ventesimo anniversario
1.0
02-27BusinesswireRDD Europe 2025, gemeinsam organisiert von Aptar Pharma und RDD Online, feiert 20-jähriges Jubiläum
1.0
02-27BusinesswireRDD Europe 2025, co-organisé par Aptar Pharma et RDD Online, fête ses 20 ans
1.0
02-27BusinesswireRDD Europe 2025, Co-Organized by Aptar Pharma and RDD Online, Celebrates 20 Years
3.0
02-22BenzingaBenzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
6.5
02-21NASDAQ.COMPeek Under The Hood: IVOO Has 16% Upside
4.5
02-13NASDAQ.COMZacks Industry Outlook Packaging Corporation of America, Amcor, AptarGroup and Sonoco Products
7.0
02-07SeekingAlphaAptarGroup projects double-digit EPS growth in 2025 backed by pharma and closures segments
4.5
02-07BenzingaWall Street Drops On Tariffs Threat, Dollar Rises, Uber Rockets On Ackman's Tweet: What's Driving Markets Friday?
3.0
02-07NASDAQ.COMRSI Alert: AptarGroup Now Oversold
4.5
02-07NASDAQ.COMFriday's ETF with Unusual Volume: AUSF
2.0
02-07NASDAQ.COMAptarGroup Q4 24 Earnings Conference Call At 9:00 AM ET
9.5
02-07NASDAQ.COMAptarGroup (ATR) Tops Q4 Earnings Estimates
9.5
02-06BusinesswireAptar Reports Fourth Quarter and Annual 2024 Results
9.5
02-06NewsfilterAptar Reports Fourth Quarter and Annual 2024 Results
People Also Watch

AGRO
Adecoagro SA
10.460
USD
+0.58%

GRC
Gorman-Rupp Co
31.360
USD
-2.03%

WOLF
Wolfspeed Inc
2.180
USD
-15.83%

AMN
AMN Healthcare Services Inc
19.470
USD
-1.37%

BKD
Brookdale Senior Living Inc
5.130
USD
-8.23%

EH
EHang Holdings Ltd
15.410
USD
-7.11%

GOOS
Canada Goose Holdings Inc
6.880
USD
-6.14%

SEAT
Vivid Seats Inc
2.450
USD
-1.61%

SBGI
Sinclair Inc
13.370
USD
+0.60%

GOGO
Gogo Inc
6.620
USD
-6.63%
FAQ

What is Aptargroup Inc (ATR) stock price today?
The current price of ATR is 133.66 USD — it has decreased -0.74 % in the last trading day.

What is Aptargroup Inc (ATR)'s business?

What is the price predicton of ATR Stock?

What is Aptargroup Inc (ATR)'s revenue for the last quarter?

What is Aptargroup Inc (ATR)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Aptargroup Inc (ATR)'s fundamentals?

How many employees does Aptargroup Inc (ATR). have?
